narsoplimab-wuug (Yartemlea)
Jump to navigation
Jump to search
Indications
* FDA-approved
Mechanism of action
- selective block of mannan-binding lectin-associated serine protease-2 (MASP-2), effector enzyme of the lectin pathway
More general terms
References
- ↑ 1.0 1.1 Ingram I First Drug for Deadly Transplant Complication Gets FDA's Blessing. Narsoplimab (Yartemlea) approved for HSCT-associated thrombotic microangiopathy. MedPage Today. December 24, 2025 https://www.medpagetoday.com/transplantation/transplantation/119200